Leeford Healthcare Limited is sharpening its play in India’s fast-growing health and personal care market with the expansion of Alite, its science-led skincare brand.

The company is leveraging its general trade network of over 1 million retail touchpoints, while simultaneously accelerating presence across quick commerce.

India’s anti-acne skincare segment, estimated at nearly $350 million in 2024, is emerging as one of the fastest-growing pockets within beauty and personal care, driven by rising incidence among younger consumers, stronger awareness around skin health, and a shift toward science-based formulations.

Amit Gupta, Founder and Managing Director of Leeford Healthcare Limited, said the company identified a key whitespace in affordable, high-efficacy formulations that encourage long-term use rather than short-term fixes.

“Our experience across 75-plus therapeutic segments has shown that outcomes are closely linked to consistency. In skincare, we saw an opportunity to bring the same approach by creating solutions consumers can use comfortably over time,” he said.

A major differentiator for the Alite portfolio is its ingredient-led positioning, reflecting a wider shift in skincare consumption where formulation transparency and proven actives are increasingly shaping purchase decisions.

The products are built around niacinamide PC for skin repair and tolerance, alongside DSBC (silanediol salicylate), a newer-generation active designed to address acne while supporting hydration and barrier repair. This multi-functional formulation strategy is aimed at bridging a noticeable gap in the mid-priced skincare segment, where next-generation actives remain underpenetrated.